Stuart Poulton - Feb 15, 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Development Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton
Stock symbol
KPTI
Transactions as of
Feb 15, 2023
Transactions value $
-$18,717
Form type
4
Date filed
2/17/2023, 03:07 PM
Previous filing
Aug 19, 2022
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$18.1K -5.67K -8.09% $3.19 64.3K Feb 15, 2023 Direct F1
transaction KPTI Common Stock Sale -$26 -8 -0.01% $3.23 64.3K Feb 15, 2023 Direct F1
transaction KPTI Common Stock Sale -$619 -196 -0.3% $3.16 64.1K Feb 15, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.